Getinge's subsidiary Maquet Cardiovascular receives adverse jury trial verdict in patent infringement dispute with Abiomed in the U.S.

GOTHENBURG, Sweden, May 28, 2026 /PRNewswire/ -- Getinge today announces that a jury in the United States District Court for the District of Massachusetts has delivered a verdict in favor of Abiomed Inc ("Abiomed") in a patent dispute between Getinge's subsidiary Maquet Cardiovascular LLC ("Maquet") and Abiomed. The jury found that Abiomed has not infringed any Maquet patents relating to intravascular heart pump technology.

PRNewsWire • May 28, 2026

IoMT Wearable Devices Patent Landscape Report and Forecasts, 2017-2023 & 2024-2032 Featuring Veniam, Advanced Neuromodulation Systems, Bionet Sonar, and Abiomed

Dublin, March 04, 2025 (GLOBE NEWSWIRE) -- The "IoMT Wearable Devices Patent Landscape Report and Forecast 2024-2032" report has been added to ResearchAndMarkets.com's offering. The IoMT wearable devices market was valued at USD 34.93 billion in 2023. It is expected to grow at a CAGR of 23.0% during the forecast period of 2024-2032 and attain a market value of USD 225.1 billion in 2032. The patent landscape is driven by advancements in sensor technology, AI integration, and connectivity solutions, enhancing diagnostic accuracy and personalised treatment. The global IoMT wearable devices patent landscape report offers an in-depth analysis of the dynamic patent environment. It explores innovations in sensor technologies, AI integration, and advanced connectivity solutions that are shaping the future of IoMT wearables. The report provides detailed segmentation by product type, modality, and application, highlighting key patents and emerging trends.

GlobeNewsWire • Mar 4, 2025

US FDA classifies recall of Abiomed's blood pumps as most serious

The U.S. health regulator on Thursday classified the recall of blood pumps by Abiomed, a Johnson & Johnson company, as the most serious and said their use could cause serious injuries or death.

Reuters • Mar 21, 2024

3 Reasons to Retain Abiomed (ABMD) Stock in Your Portfolio

Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.

Zacks Investment Research • Dec 22, 2022

FDA Approves Impella ECP Pivotal Heart Pump and First Patients Enrolled in Pivotal Clinical Trial

DANVERS, Mass.--( BUSINESS WIRE )--Abiomed (Nasdaq: ABMD) announces the United States Food and Drug Administration (FDA) has approved the version of Impella ECP that will be used in the Impella ECP Pivotal Trial, and the first two patients have been enrolled in the trial. Amir Kaki, MD, director of mechanical circulatory support at Ascension St. John Hospital in Detroit, led the procedures. This single-arm, prospective, multi-center trial will evaluate the rate of major adverse cardiovascular and cerebrovascular events (MACCE) in adult patients who receive Impella ECP support during an elective or urgent high-risk percutaneous coronary intervention (PCI).

Business Wire • Dec 21, 2022

Johnson & Johnson Announces Extension of Abiomed Tender Offer to December 21, 2022

NEW BRUNSWICK, N.J.--( BUSINESS WIRE )--Johnson & Johnson (NYSE: JNJ), the world's largest, most diversified healthcare products company, today announced that Athos Merger Sub, Inc. (“Offeror”), a wholly owned subsidiary of Johnson & Johnson, has extended the expiration date of its offer (the “Offer”) to acquire all of the outstanding shares of common stock of Abiomed, Inc. (NASDAQ: ABMD), for an upfront payment of $380.00 per share in cash, plus one non-tradeable contingent value right entitling the holder to receive up to $35.00 per share in cash if certain commercial and clinical milestones are achieved.

Business Wire • Dec 14, 2022

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ELVT, OPNT, BNFT, ABMD

NEW YORK , Dec. 6, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Elevate Credit, Inc. (NYSE: ELVT)'s  sale to an affiliate of Park Cities Asset Management LLC for $1.87 per share. If you are an Elevate Credit shareholder, click here to learn more about your rights and options.

PRNewsWire • Dec 6, 2022

First Patients in the World Treated with Impella RP Flex with SmartAssist

DANVERS, Mass.--( BUSINESS WIRE )--Abiomed (Nasdaq: ABMD) announces the first three patients in the world have been treated with Impella RP Flex with SmartAssist, Abiomed's newest heart pump for patients experiencing right heart failure. All three patients have now been successfully weaned off Impella support and two have already returned home with their native heart. The patients were treated at Hackensack University Medical Center/Hackensack Meridian Health in Hackensack, N.J., and Kingwood Medical Center in Kingwood, Texas.

Business Wire • Dec 5, 2022

Why Is Abiomed (ABMD) Up 1.2% Since Last Earnings Report?

Abiomed (ABMD) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Dec 1, 2022

Eleven Stocks Turned $10,000 To $261,421 In 11 Months

Most S&P 500 investors got a little gain this month. But investors willing to look off the beaten path found huge gains.

Investors Business Daily • Nov 30, 2022